Unlike many peptides popular in the fitness community, tesamorelin has a documented safety profile: it has been studied in randomized trials in hundreds of patients, and the FDA has approved a guideline listing adverse reactions and warnings. This makes it possible to talk about risks not with assumptions, but with facts. The editors analyze which side effects occur most often, what causes them, which ones require special attention, and how doctors monitor the safety of treatment.
How do you know about side effects?
The primary source of data on the safety of tesamorelin are two randomized, placebo-controlled phase III trials in adults with HIV and excess abdominal fat (Falutz et al., 2007; 2010) and their extension phase (Falutz et al., 2008). Together, they included hundreds of patients who received the drug for 26–52 weeks.
The presence of a placebo group is a fundamental advantage. It allows you to distinguish the side effects of the drug from the symptoms that occur in people by themselves. For example, headache or back pain often occurred in the placebo group, while joint pain and swelling were significantly more common in the tesamorelin group.
The results of these studies are summarized in the official FDA-approved Egrifta package insert. The instruction lists side reactions that occurred more often than in the placebo group, as well as individual warnings that require the attention of a doctor. It is on her that the editors rely in this material.
It is important to remember the limitations: the study participants were people with HIV on antiretroviral therapy, with careful selection and regular medical control. The profile of side effects in other groups, including self-administration of unlicensed products, may differ.
The most frequent reactions: joints, muscles, edema
The most characteristic group of side effects of tesamorelin is associated with an increase in the level of growth hormone and IGF-1. Among the reactions that occurred more often in the studies than in the placebo group, the instruction calls joint pain (arthralgia), pain in the extremities, muscle pain (myalgia) and peripheral edema.
The mechanism of these phenomena is well known from recombinant growth hormone therapy. Growth hormone contributes to the retention of sodium and water by the kidneys, which is manifested by swelling of the hands, feet and lower legs. Swelling of the soft tissues around the joints and in the muscles gives a feeling of stiffness and pain. Usually these symptoms appear in the first weeks of treatment.
Paresthesias — tingling or numbness, particularly in the hands — were also described in some patients. If the swelling compresses the median nerve in the carpal tunnel, carpal tunnel syndrome develops with numbness of the fingers, especially at night. Such symptoms are a reason to consult a doctor.
In most patients, these reactions were mild to moderate and often decreased over time or after discontinuation of the drug. However, they were one of the reasons why some study participants stopped treatment. For people who already have joint diseases or a tendency to swelling, this aspect is especially important.
Injection site reactions and hypersensitivity
Because tesamorelin is administered subcutaneously daily, injection site reactions are one of the most common complaints. The instructions describe redness, itching, pain, irritation, swelling and bleeding at the injection site. To reduce the risk, it is recommended to alternate areas on the abdomen and not to inject the drug into areas with scars, bruises or irritation.
The issue of hypersensitivity reactions is separate. Studies have reported rash, hives, itchy skin, facial flushing, and in isolated cases more severe reactions with swelling of the face or throat, rapid heartbeat, and shortness of breath. The instruction requires to immediately stop the treatment and seek medical help if such symptoms appear.
The formation of antibodies is also related to the immune system. According to the instructions, IgG antibodies to tesamorelin were detected in about half of the patients during treatment. No clear impact of these antibodies on efficacy or safety has been established in research, but their clinical significance with long-term use has not been definitively clarified.
It is practically important to distinguish between the expected local reaction, which passes in a day or two, and signs of infection or allergy: growing pain, spreading redness, fever, generalized rash. The latter require a medical assessment.
Glucose metabolism and IGF-1
Growth hormone reduces the sensitivity of tissues to insulin, so drugs that increase its level can worsen glucose tolerance. In studies of tesamorelin, a small but statistically significant increase in glucose levels was observed in some patients, and the instructions contain a warning about the increased risk of developing disorders of carbohydrate metabolism, in particular diabetes.
Therefore, it is recommended to assess the state of carbohydrate metabolism before starting treatment, and periodically monitor glucose and glycated hemoglobin during therapy. Patients with diabetes may need adjustment of glucose-lowering therapy. If glycemic control worsens, the physician should consider continuing treatment.
| Indicator | Why control? | What may require a doctor's response |
|---|---|---|
| Glucose, HbA1c | Risk of insulin resistance and diabetes | Steady increase, symptoms of hyperglycemia |
| IGF-1 | Assessment of the intensity of stimulation of the GR axis | A steady rise above the age norm |
| Swelling, joint pain | Signs of fluid retention | Severe or progressive symptoms |
| Skin at injection sites | Local and allergic reactions | A widespread rash, signs of infection |
| Efficiency | Reduction in waist circumference / visceral fat | No response after several months |
Another mandatory parameter is IGF-1. Since tesamorelin increases its level, and a long-term excess of IGF-1 is theoretically associated with risks for tissues that are prone to proliferation, the instructions recommend monitoring this indicator. With persistently high IGF-1, especially in combination with other risk factors, the doctor may consider stopping therapy.
Also, the instructions recommend evaluating the effectiveness and not continuing the treatment if there is no noticeable reduction in visceral fat. This "benefit should outweigh the risk" principle for drugs with systemic effects on hormones is key.
Contraindications and special situations
In addition to adverse reactions, the instructions specify the conditions under which tesamorelin cannot be used. They logically follow from the mechanism of action and the potential risks of increasing growth hormone.
- Disruption of the hypothalamus–pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor, surgery, head irradiation, or trauma.
- Active malignant neoplasms — due to the mitogenic effect of IGF-1; in patients with an oncological history, decisions are made especially carefully.
- Hypersensitivity to tesamorelin or mannitol (an excipient).
- Pregnancy - reducing visceral fat is not beneficial for a pregnant woman, and a possible effect on the fetus is not excluded.
A separate caveat applies to acute critical conditions. Studies of recombinant growth hormone have shown increased mortality in critically ill patients after major surgery, trauma, or acute respiratory failure. Although there are no such data for tesamorelin, the instructions advise to consider stopping the drug in such situations.
For breastfeeding, the instructions also contain warnings, and for children and adolescents, safety and effectiveness have not been established. The use of tesamorelin for sports purposes, in addition to the medical risks, is a violation of anti-doping rules: the drug is directly named in section S2 of the WADA Prohibited List.
And finally, the safety profile described in the instructions refers to the original pharmaceutical product. For tesamorelin purchased outside the pharmacy network, the risks of unknown content, impurities and impaired sterility are added.
Editorial conclusion
The most common side effects of tesamorelin are joint and limb pain, myalgia, peripheral edema, and injection site reactions. They are mostly mild or moderate and are due to increased growth hormone and fluid retention.
More serious warnings concern glucose metabolism, hypersensitivity reactions, antibody formation, and prolonged elevation of IGF-1. That is why the treatment is accompanied by regular laboratory control.
Contraindications — disruption of the pituitary axis, active oncological diseases, hypersensitivity and pregnancy — directly follow from the mechanism of action of the drug.
We also recommend reading our articles Tesamorelin Long-Term Risks: What We Know Today, Tesamorelin: Human and Animal Results, and Side Effects of CJC-1295 for a comparison with the non-registered counterpart.
References
- EGRIFTA (tesamorelin for injection). Prescribing information. Theratechnologies Inc.; U.S. Food and Drug Administration.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359â2370.
- Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719â1728.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291â4304.
- Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821âe830.
- World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List. Montreal: WADA; current edition.
